Clinical Trial

Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain

Study acronym: T-ROSS-II
Completed
View on ClinicalTrials.gov →
Summary
Observational retrospective study to characterize and assess clinical outcomes of patients receiving tezepelumab after marketing approval in Spain
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-06-06; most recent amendment 2026-01-09.
Status change: Recruiting → Completed 2026-01-09
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT07013760
Lead Sponsor AstraZeneca
Conditions Asthma
Enrollment 420 participants
Start Date 2025-06-23
Primary Completion 2025-12-19 (estimated)
Study Completion 2025-12-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-12